Ivermectin & Methylene Blue: Early Cancer Research & Potential Treatments

Early research is exploring ivermectin and methylene blue for their potential in cancer treatment. While these findings are primarily from lab or animal studies, they offer intriguing insights into new therapeutic avenues. Ivermectin, known as an anti-parasitic, has shown promise in slowing cancer cell growth, triggering cell death (apoptosis), and affecting key signaling pathways involved in cancer progression. Methylene blue, historically used for methemoglobinemia, has demonstrated potential to disrupt cancer cell metabolism and increase oxidative stress in tumor cells, possibly making them more vulnerable to treatment, with some research exploring its role in photodynamic therapy (PDT). IMPORTANT: Neither drug is currently approved for cancer therapy, and human clinical trials are limited or still in progress. This video discusses investigational research and should not be taken as medical advice. Always consult with a qualified healthcare professional for cancer treatment. #CancerResearch #Ivermectin #MethyleneBlue #CancerTreatment #DrugRepurposing #AntiCancer #PreclinicalStudies #HumanTrials #MedicalScience #Oncology #ExperimentalTherapy #LabStudies #TumorCells #Apoptosis #PhotodynamicTherapy #FutureMedicine #HealthResearch